Stocks · News reference
Kazia Therapeutics shares are trading lower after the company announced pricing of up to $120 million public offering.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Kazia Therapeutics Reports New Preclinical And Translational Data Showing Lead Asset Paxalisib Reduced Tumor Burden By 52% In MSS/pMMR Colorectal Cancer
Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further ReductionPaxalisib Was Well Tolerated as Monotherapy and
Kazia Therapeutics Announces New Preclinical Data Showing Safety, Anti-Tumor Activity Of Paxalisib In HR+/HER2- Breast Cancer; First Patient Expected By Year-End 2026 And Full Enrollment By End Of 2027
Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor ActivityThree-Arm Expansion of the Ongoing TNBC Trial Will Evaluate Paxalisib
Kazia Therapeutics Announces Pricing Of $40M Underwritten Offering Of ADSs And Pre-Funded Warrants